Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

BACKGROUND: In the PALOMA-3 study, palbociclib plus fulvestrant demonstrated improved progression-free survival compared with fulvestrant plus placebo in hormone receptor-positive, HER2− endocrine-resistant metastatic breast cancer (MBC). This analysis compared patient-reported outcomes (PROs) betwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., Puyana Theall, K., Bartlett, C. H., Loibl, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880065/
https://www.ncbi.nlm.nih.gov/pubmed/27029704
http://dx.doi.org/10.1093/annonc/mdw139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880065/
https://www.ncbi.nlm.nih.gov/pubmed/27029704
http://dx.doi.org/10.1093/annonc/mdw139

Ejemplares similares